Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Increased sensitivity to phenprocoumon during methyltestosterone therapy

  • 20 Accesses

  • 4 Citations


Abnormal sensitivity to phenprocoumon in a castrated male who was receiving substitution therapy with methyltestosterone, has been studied and compared with pharmacokinetic data obtained from six control subjects, all of whom had cardiac disorders. The concentration-effect relationship for phenprocoumon in the castrated patient was evaluated by the mathematical model described by Nagashima et al. (1969). The possible mechanisms involved in sensitization by methyltestosterone of the response to phenprocoumon are discussed. It is suggested that methyltestosterone increases the affinity of the receptor sites in the liver for phenprocoumon, an effect which has previously been attributed to other C17-alkyl-substituted androgens.

This is a preview of subscription content, log in to check access.


  1. 1.

    Allington, M.J.: Owren's method for the control of anticoagulant therapy. J. clin. Path.11, 62–68 (1958)

  2. 2.

    Andreasen, F.: Protein binding of drugs in plasma from patients with acute renal failure. Acta pharmacol. (Kbh.)32, 417–429 (1973)

  3. 3.

    Chriske, H.W., Smekal, P.V., Knabe, M., Kray, D.: Pharmakokinetische Untersuchungen bei erhöhter Ansprechbarkeit gegenüber Phenprocoumon (Marcoumar®). Med. Welt (Stuttg.)24, 1620–1621 (1973 a)

  4. 4.

    Chriske, H.W., Gross, R., Hilger, H.H., Oette, K., Smekal, P.V., Knabe, M., Kray, D.: Pharmakokinetische Untersuchungen zur Phenprocoumon (Marcoumar®)-Resistenz. Verh. dtsch. Ges. inn. Med.79, 1311–1314 (1973 b)

  5. 5.

    Coon, W.W., Willis, P.W.: Some aspects of the pharmacology of oral anticoagulants. Clin. Pharmacol. Ther.11, 312–336 (1970)

  6. 6.

    Dresdale, F.C., Hayes, J.C.: Potential dangers in the combined use of methandrostenolone and sodium warfarin. J. med. Soc. N.J.64, 609–612 (1967)

  7. 7.

    Eipe, J.: Drugs affecting therapy with anticoagulants. Med. Clin. North Amer.56, 255–262 (1972)

  8. 8.

    Foged, L., Husted, S., Andreasen, F.: Reduced binding of phenprocoumon (Marcoumar®) to HSA in the presence of furosemid. Acta pharmacol. (Kbh.)

  9. 9.

    Formiller, M., Cohon, M.S.: Coumarin and indandione anticoagulants. Potentiators and antagonists. Amer. J. Hosp. Pharm.26, 574–582 (1969)

  10. 10.

    Furman, R.H., Howard, R.P., Alaupovic, P.: Reduction in serum lipid levels during oral administration of C17-alkylated steroids, methyltestosterone and methylandrostanopyrazole, to hyperlipemic subjects. J. Lab. clin. Med.60, 876 (1962)

  11. 11.

    Gugler, R.: Beeinflussung der Wirkung oraler Antikoagulantien durch andere Pharmaka. Med. Welt (Stuttg.)25, 12–15 (1974)

  12. 12.

    Koch-Weser, J., Sellers, E.M.: Drug interactions with coumarin anticoagulants. New Engl. J. Med.285, 487–498 and 547 – 559 (1971)

  13. 13.

    Levy, G.: Relationship between rate of elimination of tubocurarine and rate of decline of its pharmacologic activity. Brit. J. Anaesth.36, 694–695 (1964)

  14. 14.

    Levy, G.: Kinetics of pharmacologic effects. Clin. Pharmacol. Ther.7, 362–372 (1966)

  15. 15.

    Levy, G.: Kinetics of pharmacologic activity of succinylcholine in man. J. pharm. Sci.56, 1687–1688 (1967)

  16. 16.

    Levy, G.: Pharmacokinetics of succinylcholine in newborns. Anesthesiol.32, 551–552 (1970)

  17. 17.

    Levy, G., O'Reilly, R.A., Aggeler, P.M., Keech, G.M.: Pharmacokinetic analysis of the effect of barbiturates on the anticoagulant action of warfarin in man. Clin. Pharmacol. Ther.11, 372–377 (1970)

  18. 18.

    Levy, G.: Comparative pharmacokinetics of the anticoagulant effect of coumarin drugs in man and rat. J. Pharmacokinet. Biopharm.1, 541–551 (1973)

  19. 19.

    Lowenthal, J., MacFarlane, J.A.: The nature of the antagonism between vitamin-K and in-direct anticoagulants. J. Pharmacol. exp. Ther.143, 273–277 (1964)

  20. 20.

    Marquardt, G.H., Fischer, C.I., Levy, P., Dowben, R.M.: Effect of anabolic steroids on liver function tests and creatinine excretion. J. Amer. med. Ass.175, 851–853, (1961)

  21. 21.

    Murakami, M., Odake, K., Matsuda, T., Onchi, K., Umeda, T., Nishino, T.: Effects of anabolic steroids on anticoagulant requirements. Jap. Circulat. J. (En.)29, 243–250 (1965)

  22. 22.

    Nagashima, R., O'Reilly, R.A., Levy, G.: Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin. Clin. Pharmacol. Ther.10, 22–35 (1969)

  23. 23.

    O'Reilly, R.A., Aggeler, P.M.: Determinants of the response to oral anticoagulant drugs in man. Pharmacol. Rev.22, 35–96 (1970)

  24. 24.

    O'Reilly, R.A., Aggeler, P.M., Hoag, M.S., Leong, L.S., Kropatkin, M.L.: Heriditary transmission of exceptional resistance to coumarin anticoagulant drugs. The first reported kindred. New Engl. J. Med.271, 809–815 (1964)

  25. 25.

    O'Reilly, R.A., Levy, G.: Pharmacokinetic analyses of potentiating effect of phenylbutazone on anticoagulant action of warfarin in man. J. pharm. Sci.59, 1258–1261 (1970 a)

  26. 26.

    O'Reilly, R.A., Levy, G.: Kinetics of the anticoagulant effect of bishydroxycoumarin in man. Clin. Pharmacol. Ther.11, 378–384 (1970 b)

  27. 27.

    Pliska, V.: On the in vivo kinetics of drug action. Arzneimittel-Forsch.16, 886–893 (1966)

  28. 28.

    Pyörälä, K., Kekki, M.: Decreased anticoagulant tolerance during methandrostenolone therapy. Scand. J. clin. Lab. Invest.15, 367–374 (1963)

  29. 29.

    Pyörälä, K., Myllylä, G., Kekki, M.: Metabolism of warfarin during methandrostenolone treatment. Ann. Med. exp. Fenn.43, 95–97 (1965)

  30. 30.

    Raheja, K.L., Reber, E.F., Anderson, D.L.: Effect of vitamin K3 and testosterone propionate on plasma cholesterol level and prothrombin rate in castrated and intact rats. Indian J. Physiol. Pharmacol.15, 143–150 (1971)

  31. 31.

    Schrogie, J.J., Solomon, H.M.: The anticoagulant response to bishydroxycoumarin. II. The effect of D-thyroxine, clofibrate and norethandrolene. Clin. Pharmacol. Ther.8, 70–77 (1967)

  32. 32.

    Seiler, K., Duckert, F.: Properties of 3-(1-phenyl-propyl)-4-oxycoumarin (Marcoumar®) in the plasma when tested in normal cases and under the influence of drugs. Thrombos. Diathes. haemorrh. (Stuttg.)19, 389–396 (1968)

  33. 33.

    Solomon, H.M., Schrogie, J.J.: The anticoagulant response to bishydroxycoumarin. I. The role of individual variation. Clin. Pharmacol. Ther.8, 65–69 (1967 a)

  34. 34.

    Solomon, H.M., Schrogie, J.J.: Change in receptor affinity: A proposed explanation for the potentiation effect of D-thyroxine on the anticoagulant response to warfarin. Clin. Pharmacol. Ther.8, 797–799 (1967 b)

  35. 35.

    Stenbjerg, S., Husted, S., Mygind, K.: A circulation factor V inhibitor: Possible side effect of treatment with streptomycin. Scand. J. Haemat.14, 280–285 (1975)

  36. 36.

    Toohey, M.: Comparison of Quick's, Owren's, and Ware's techniques for the control of anticoagulant therapy. J. clin Path.11, 56–61 (1958)

  37. 37.

    Woolf, I.L., Babior, B.M.: Vitamin-K and warfarin: Metabolism, function and interaction. Amer. J. Med.53, 261–267 (1972)

  38. 38.

    Wynn, V., Landon, J., Kawerau, E.: Studies of hepatic function during methandienone therapy. Lancet1961 I, 69–75

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Husted, S., Andreasen, F. & Foged, L. Increased sensitivity to phenprocoumon during methyltestosterone therapy. Eur J Clin Pharmacol 10, 209–216 (1976).

Download citation

Key words

  • Phenprocoumon
  • anticoagulants
  • concentration-effect curves
  • methyltestosterone
  • interaction